Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

262 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The multimorbidity collaborative medication review and decision making (MyComrade) study: a pilot cluster randomised trial in two healthcare systems.
Kirwan C, Hynes L, Hart N, Mulligan S, Leathem C, McQuillan L, Maxwell M, Carr E, Roche K, Walkin S, McCarthy C, Bradley C, Byrne M, Smith SM, Hughes C, Corry M, Kearney PM, McCarthy G, Cupples M, Gillespie P, Hobbins A, Newell J, Glynn L, Roshan D, Sinnott C, Murphy AW. Kirwan C, et al. Among authors: mulligan s. Pilot Feasibility Stud. 2022 Oct 4;8(1):225. doi: 10.1186/s40814-022-01107-y. Pilot Feasibility Stud. 2022. PMID: 36195963 Free PMC article.
The MultimorbiditY COllaborative Medication Review And DEcision Making (MyComrade) study: a protocol for a cross-border pilot cluster randomised controlled trial.
Hynes L, Murphy AW, Hart N, Kirwan C, Mulligan S, Leathem C, McQuillan L, Maxwell M, Carr E, Walkin S, McCarthy C, Bradley C, Byrne M, Smith SM, Hughes C, Corry M, Kearney PM, McCarthy G, Cupples M, Gillespie P, Newell J, Glynn L, Alvarez-Iglesias A, Sinnott C. Hynes L, et al. Among authors: mulligan s. Pilot Feasibility Stud. 2022 Mar 28;8(1):73. doi: 10.1186/s40814-022-01018-y. Pilot Feasibility Stud. 2022. PMID: 35346380 Free PMC article.
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.
Tam CS, Opat S, D'Sa S, Jurczak W, Lee HP, Cull G, Owen RG, Marlton P, Wahlin BE, García-Sanz R, McCarthy H, Mulligan S, Tedeschi A, Castillo JJ, Czyż J, Fernández De Larrea C, Belada D, Libby E, Matous J, Motta M, Siddiqi T, Tani M, Trněný M, Minnema MC, Buske C, Leblond V, Treon SP, Trotman J, Wu B, Yu Y, Shen Z, Chan WY, Schneider J, Allewelt H, Cohen A, Dimopoulos MA. Tam CS, et al. Among authors: mulligan s. Blood Adv. 2024 Apr 9;8(7):1639-1650. doi: 10.1182/bloodadvances.2023010906. Blood Adv. 2024. PMID: 38315878 Free PMC article.
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group; Horby PW, Peto L, Staplin N, Campbell M, Pessoa-Amorim G, Mafham M, Emberson JR, Stewart R, Prudon B, Uriel A, Green CA, Dhasmana DJ, Malein F, Majumdar J, Collini P, Shurmer J, Yates B, Baillie JK, Buch MH, Day J, Faust SN, Jaki T, Jeffery K, Juszczak E, Knight M, Lim WS, Montgomery A, Mumford A, Rowan K, Thwaites G, Haynes R, Landray MJ. RECOVERY Collaborative Group, et al. Nat Commun. 2024 Jan 31;15(1):924. doi: 10.1038/s41467-023-43644-x. Nat Commun. 2024. PMID: 38296965 Free PMC article. Clinical Trial.
Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon.
Lew TE, Bennett R, Lin VS, Whitechurch A, Handunnetti SM, Marlton P, Shen Y, Mulligan SP, Casan J, Blombery P, Tam CS, Roberts AW, Seymour JF, Thompson PA, Anderson MA. Lew TE, et al. Among authors: mulligan sp. Blood Adv. 2024 Mar 26;8(6):1439-1443. doi: 10.1182/bloodadvances.2023011327. Blood Adv. 2024. PMID: 38231032 Free PMC article. No abstract available.
262 results